TBCRC 023: A Randomized Multicenter Phase II Neoadjuvant Trial of Lapatinib Pus Trastuzumab, With or Without Endocrine Therapy for 12 Weeks vs. 24 Weeks in Patients With HER2 Overexpressing Breast Cancer.

Trial Profile

TBCRC 023: A Randomized Multicenter Phase II Neoadjuvant Trial of Lapatinib Pus Trastuzumab, With or Without Endocrine Therapy for 12 Weeks vs. 24 Weeks in Patients With HER2 Overexpressing Breast Cancer.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Dec 2017

At a glance

  • Drugs Lapatinib (Primary) ; Trastuzumab (Primary) ; Letrozole
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms HELEX
  • Most Recent Events

    • 09 Dec 2017 Results assessing HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy (n=85) presented at the 40th Annual San Antonio Breast Cancer Symposium
    • 10 Jun 2017 Biomarkers information updated
    • 22 Jul 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top